| 标题 |
2592MO Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): Results from phase III part of a randomized, open-label, active-controlled phase II/III study (FRUSICA-2) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:Dingwei Ye; Zhanwen He; Yuanyuan Qu; Xuejun Zhang; Xin Yao; et al 出版日期:2025-09-01 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)